Results 121 to 130 of about 4,182 (143)

Population-based cohort study assessing the effectiveness of maternal BNT162b2/mRNA-1273 vaccination against infant coronavirus disease 2019 outcomes during Omicron predominance: The VENUS study. [PDF]

Hum Vaccin Immunother
Ishiguro C, Mimura W, Oda F, Maeda M, Fukuda H.   +4 more
europepmc   +1 more source

Prospective Evaluation of Antibody Response post COVID-19 vaccination in older persons ≧ 60 years old (PEARL 60): A longitudinal 15-months study in a tertiary centre in Malaysia. [PDF]

PLoS One
Hasmukharay K, Verma AK, Aravindhan K, Alagappan PRS, Kamal AKM, Zulhaimi NS, Saedon NI, I-Ching-Sam J, Pin TM, Rajasuriar R.   +9 more
europepmc   +1 more source

Statistical Modeling of Humoral Immune Response Dynamics to mRNA COVID-19 Vaccines in Nursing Home Residents and Healthcare Workers from Southern Italy. [PDF]

Viruses
Domma F, Soraci L, Paparazzo E, Amerise I, Aceto MA, Cassano TS, Bellizzi D, Cosimo SC, Morelli F, Corsonello A, Passarino G, Montesanto A.   +11 more
europepmc   +1 more source

Post-booster longitudinal plasma proteomic changes following BNT162b2 COVID-19 vaccination in Qatar. [PDF]

Front Immunol
Bentebbal S, Zaqout A, Meqbel B, Bensmail I, Aldushain A, de la Fuente A, Thomas R, Naik A, Shaath H, Al-Akl NS, Adam A, Moussa HYA, Shin KC, Taha RZ, Abukhattab M, Al-Maslamani MA, Alajez NM, Arredouani A, Park Y, Abdulla SA, El-Agnaf OMA, Abdesselem HB, Omrani AS, Decock J.   +23 more
europepmc   +1 more source

Dose-dependent IFN programs in myeloid cells after mRNA and adenovirus COVID-19 vaccination. [PDF]

JCI Insight
Eryilmaz G, Yazici YY, Marches R, Mimitou EP, Kenyon-Pesce L, Handrejk K, Jangra S, Schotsaert M, García-Sastre A, Kuchel GA, Banchereau J, Ucar D.   +11 more
europepmc   +1 more source

Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform. [PDF]

PLoS One
Volkman HR, de Munter L, Nguyen JL, Tran TMP, Mitratza M, Marques C, Choi L, Valluri S, Yang J, Antón A, Casas I, Conde-Sousa E, Drikite L, Grüner B, Icardi G, Ten Kate GL, Martin C, Mira-Iglesias A, Orrico-Sánchez A, Otero-Romero S, Rohde G, Jodar L, McLaughlin JM, Bollaerts K.   +23 more
europepmc   +1 more source

Seven-month persistence of COVID-19 vaccine-induced lymphadenopathy: a case report. [PDF]

J Med Case Rep
Hwang MK, Dua H, Mulligan AM, Escallon J.   +3 more
europepmc   +1 more source

<i>CMTM8</i> variants influence BNT162b2 COVID-19 vaccination response by regulating granulocytic/polymorphonuclear myeloid-derived suppressor cell activity. [PDF]

Front Immunol
Testori A, Mulas A, Marongiu M, Orrù V, Lobina M, Piras MG, Lutzu E, Curreli N, Politi C, Mobrici M, Iervasi G, Corda D, De Felice M, Testa A, Devoto M, Steri M, Fiorillo E, SerGenCovid-19 Investigators.   +17 more
europepmc   +1 more source

Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic mechanisms. [PDF]

Oncotarget
Gentilini P, Lindsay JC, Konishi N, Fukushima M, Polykretis P.   +4 more
europepmc   +1 more source

Cellular immune responses 12 months after fractional or standard dose BNT162b2 booster vaccination in Mongolian adults. [PDF]

Front Immunol
Mazarakis N, Toh ZQ, Batmunkh T, Anderson J, Quah L, Ng YY, Amraa O, Burentogtokh T, Jigjidsuren S, Altangerel B, Namjil N, Mashbaatar K, Carissa R, Luu S, Moore KA, Neal EFG, Nguyen C, Li S, Hart J, Do LAH, Justice F, Mulholland K, von Mollendorf C, Licciardi PV.   +23 more
europepmc   +1 more source